BioCryst Pharmaceuticals | L'Utile Ante Imposte





L'Utile Ante Imposte Cambiamento Data
Alnylam Pharmaceuticals USD 238.97M 274.33M 2025-09
BioCryst Pharmaceuticals USD -86.95M 73.5M 2024-12
Chugai Pharma JPY 169.9B 13.83B 2025-12
Daiichi Sankyo JPY 106.73B 48.96B 2025-12
DBV Technologies USD -33.16M 8.6M 2025-09
Enanta Pharmaceuticals USD -22.71M 95.08M 2024-12
Gilead Sciences USD 3.64B 1.21B 2025-09
GlaxoSmithKline GBP 1.23B 1.23B 2025-12
Glaxosmithkline GBP 2.46B 569M 2025-09
Incyte USD 482.31M 75.7M 2025-09
Ionis Pharmaceuticals USD -129M 253M 2025-09
Karyopharm Therapeutics USD -30.89M 1.16M 2024-12
Neurocrine Biosciences USD 291.8M 132.3M 2025-09
Novavax USD -122.33M 286.92M 2024-09
PTC Therapeutics USD -23.07M 47.98M 2025-09
Regeneron Pharmaceuticals USD 1.76B 244.6M 2025-09
Roche Holding CHF 4.79B 3.01B 2025-06
Sarepta Therapeutics USD -194.05M 347.69M 2025-09
Ultragenyx Pharmaceutical USD -179.54M 65.54M 2025-09
Vertex Pharmaceuticals USD 1.3B 15.8M 2025-09


BioCryst Pharmaceuticals L'Utile Ante Imposte - Valori correnti, dati storici, previsioni, statistiche, grafici e calendario economico - Feb 2026.